Skip to content

Clinical trials

Phase 3 Central Nervous System Diseases trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Central Nervous System Diseases Phase: Phase 3 Country / region: Canada Clear all

13 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20121
20131
20151
20162
20171
20182
20191
20201
20211
20231
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed7
Terminated5
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AbbVie3
AstraZeneca2
Otsuka Pharmaceutical Development & Commercialization, Inc.2
Alzheon Inc.1
Eli Lilly and Company1
Emalex Biosciences Inc.1
GlaxoSmithKline1
Hoffmann-La Roche1
Remedy Pharmaceuticals, Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Central Nervous System Diseases13
Brain Diseases11
Nervous System Diseases10
Neurodegenerative Diseases8
Mental Disorders7
Movement Disorders6
Alzheimer Disease4
Dementia4
Tauopathies4
Neurocognitive Disorders3

Trials

Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.